Hanmi Science disclosed on May 3rd its provisional first-quarter 2024 results, showcasing robust financial performance. Consolidated sales surged to $236 million, accompanied by operating profit of $27.5 million and net profit of $22.9 million. Compared to the same period last year, sales expanded by 9.9%, operating profit by 19%, and net profit by 16.4%.

A spokesperson from Hanmi Science attributed the impressive results to the consistent improvement in performance among its core affiliates and notable achievements in the healthcare business sector

In the healthcare business segment, which has been consolidating since the 2022 merger, sales rose by 10.1% from the previous year to $22.5 million. Meanwhile, the pharmaceutical wholesale sector, represented by Online Pharm, saw sales totaling $201 million.

Hanmi Science also revealed plans to leverage synergies among its subsidiaries through strategic investments and collaborations with promising entities such as 'Evidnet', a medical data specialist company, 'BloomLife', a U.S. venture focusing on medical devices for pregnant women and professional platforms, and 'Alpha Tau Medical', an Israeli medical device specialist.

The spokesperson further emphasized, "The first quarter demonstrated Hanmi Science's capabilities as a business model holding company with proprietary sales, setting the trajectory for future endeavors." They added, "We are committed to showcasing innovative potential in response to the rapidly evolving global healthcare landscape, thereby enhancing corporate and shareholder value."